Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01960946 · ClinicalTrials.gov registry record · NA
Galectin-3 Blockade in Patients With High Blood Pressure
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT01960946: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01960946 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01960946, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
This study will investigate if Modified Citrus Pectin (MCP) can help people with high blood pressure. MCP is a dietary supplement that is derived from plants, and therefore is not subject to approval by the U.S. Food and Drug Administration (FDA). However, MCP has been deemed as 'generally regarded as safe' by the FDA. This study will examine whether Modified Citrus Pectin (MCP) can help people with high blood pressure. The study will help understand how MCP may affect the risk for heart disease in patients with high blood pressure.
Interventions
- DIETARY_SUPPLEMENT Modified Citrus Pectin (MCP) vs placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-08-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01960946
The ClinicalTrials.gov registry entry for NCT01960946 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Modified Citrus Pectin (MCP) vs placebo is the first listed.
NCT01960946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01960946 about?
NCT01960946 is a clinical study titled "Galectin-3 Blockade in Patients With High Blood Pressure". This study will investigate if Modified Citrus Pectin (MCP) can help people with high blood pressure. MCP is a dietary supplement that is derived from plants, and therefore is not subject to approval by the U.S. Food and Drug Administration (FDA). However, MCP has been deemed as 'generally regarded ...
What is the current status of trial NCT01960946?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2013-10. Estimated completion is 2018-08-30.
What interventions are being tested in trial NCT01960946?
The interventions under investigation include: Modified Citrus Pectin (MCP) vs placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01960946?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.